{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DMARD+Therapy&page=2", "query": { "intervention": "DMARD Therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DMARD+Therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T22:26:13.113Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01521923", "title": "A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol + Methotrexate (MTX)", "type": "BIOLOGICAL" }, { "name": "Placebo + Methotrexate (MTX)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 359, "start_date": "2012-01", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01521923" }, { "nct_id": "NCT00966875", "title": "A Study in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "LY2439821", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 448, "start_date": "2009-08", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2016-05-26", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 37, "location_summary": "Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00966875" }, { "nct_id": "NCT04134728", "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "GSK3196165 (Otilimab)", "type": "BIOLOGICAL" }, { "name": "Sarilumab", "type": "BIOLOGICAL" }, { "name": "Placebo to GSK3196165/ Sarilumab", "type": "DRUG" }, { "name": "csDMARDs", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2019-10-31", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 46, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134728" }, { "nct_id": "NCT00424294", "title": "A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "CP-195,543", "type": "DRUG" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2006-06", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2014-09-25", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 39, "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Upland, California + 35 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Upland", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424294" }, { "nct_id": "NCT01476956", "title": "Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Observational study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "CARE ARTHRITIS LTD.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 571, "start_date": "2011-10", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 5, "location_summary": "Baltimore, Maryland • New York, New York • Rochester, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476956" }, { "nct_id": "NCT02557100", "title": "Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-11-19", "completion_date": "2019-03-28", "has_results": true, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02557100" }, { "nct_id": "NCT01197534", "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "fostamatinib", "type": "DRUG" }, { "name": "placebo, fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 913, "start_date": "2010-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01197534" }, { "nct_id": "NCT05413044", "title": "A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140706, "start_date": "2019-07-01", "completion_date": "2025-10-31", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413044" }, { "nct_id": "NCT00124982", "title": "Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)", "type": "DRUG" }, { "name": "Anti-Tumor Necrosing Factor (TNF) Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1286, "start_date": "2005-04", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2012-02-27", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124982" }, { "nct_id": "NCT02584855", "title": "A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 394, "start_date": "2015-09-14", "completion_date": "2018-10-30", "has_results": true, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-09-16T22:26:13.113Z", "location_count": 22, "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584855" } ] }